Drug Use and Dosage in Renal Failure

Comprehensive Pediatric Nephrology

Volumn , Issue , 2008, Pages 991-1002

  Blowey, Douglas L ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882868832     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04883-5.50070-2     Document Type: Chapter

References (169)

1. Ritschel W, Kearns GL Handbook of basic pharmacokinetics, fifth edition 1999, American Pharmaceutical Association, Washington, D.C.
2. Borst P, Elferink RO Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71:537-592.
3. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003, 42(6):1253-1259.
4. Strolin BM, Whomsley R, Baltes EL Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005, 1(3):447-471.
5. Holstege CP, Mitchell K, Barlotta K, Furbee RB Toxicity and drug interactions associated with herbal products: Ephedra and St. John's Wort. Med Clin North Am 2005, 89(6):1225-1257.
6. Hare JT, Elliott DP Grapefruit juice and potential drug interactions. Consult Pharm 2003, 18(5):466-472.
7. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997, 62:41-49.
8. Katari SR, Magnone M, Shapiro R, et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant 1997, 11(3):237-242.
9. Haufroid V, Mourad M, Van KV, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004, 14(3):147-154.
10. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005, 19(5):638-643.
11. Berkovitch M, Bitzan M, Matsui D, Finkelstein H, Balfe JW, Koren G Pediatric clinical use of the ketoconazole/cyclosporin interaction. Pediatr Nephrol 1994, 8:492-493.
12. El-Dahshan KF, Bakr MA, Donia AF, Badr A, Sobh MA Ketocon-azole-tacrolimus coadministration in kidney transplant recipients: Two-year results of a prospective randomized study. Am J Nephrol 2006, 26(3):293-298.
13. Ernest D, Cutler DJ Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med 1992, 20(5):586-589.
14. Hamann SR, Oeltgen PR, Shank WA, Blouin RA, Natarajan L Evaluation of gentamicin pharmacokinetics during peritoneal dialysis. Ther Drug Monit 1982, 4(3):297-300.
15. Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995, 346(8968):145-147.
16. Ball M, McQuay HJ, Moore RA, Allen MC, Fisher A, Sear J Renal failure and the use of morphine in intensive care. Lancet 1985, 1(8432):784-786.
17. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977, 86(6):738-741.
18. Leeder JS Drug biotransformation. Handbook of basic pharmacokinetics 1999, 134-155. American Pharmaceutical Association, Washington, D.C. W. Ritschel, G.L. Kearns (Eds.).
19. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE Developmental pharmacology: Drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
20. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med 1988, 84(5):911-918.
21. Odugbemi T An open evaluation study of sulbactam/ampicillin with or without probenecid in the treatment of gonococcal infections in Lagos. Drugs 1988, 35(7):89-91.
22. Prescott L, Balali-Mood M, Critchley J, Johnstone A, Proudfoot A Diuresis or urinary alkalinisation for salicylate poisoning. Br Med J 1982, 285:1383-1386.
23. Arant BS Developmental patterns of renal functional maturation in the human neonate. J Pediatr 1978, 92(5):705-712.
24. Schwartz G, Brion LP, Spitzer A The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clinics North Am 1987, 34(3):571-590.
25. Bailie GR, Johnson CA, Mason NA, St Peter WL Peritoneal dialysis: A guide to medication use 2005, Nephrology Pharmacy Associates, Shirley, N.Y.
26. Warady BA, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 2000, 20(6):610-624.
27. Taketomo CK, Hodding JH, Kraus DM Pediatric Dosage handbook, eleventh edition 2004, Lexi-comp, Hudson, OH.
28. Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: Special considerations in pediatric patients. Paediatr Drugs 2004, 6(1):45-65.
29. Boelaert J, Schurgers M, Daneels R, Van Landuyt HW, Weatherley BC Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1987, 20(1):69-76.
30. Laskin OL, Longstreth JA, Whelton A, et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982, 73(1A):197-201.
31. Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Nephron 1996, 74(2):337-341.
32. Wagstaff AJ, Faulds D, Goa KL Aciclovir: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47(1):153-205.
33. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982, 17(1):19-23.
34. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002, 51(RR-3):1-31.
35. Olyaei AJ, de Mattos A, Bennett W Prescribing drugs in renal disease. The kidney 2000, 2606-2653. W. B. Saunders, Philadelphia. B. Brenner (Ed.).
36. Chow-Tung E, Lau AH, Vidyasagar D, John EG Effect of peritoneal dialysis on serum concentrations of three drugs commonly used in pediatric patients. Dev Pharmacol Ther 1985, 8(2):85-95.
37. Lanao JM, Dominguez-Gil A, Tabernero JM, Macias JF Influence of type of dialyzer on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol 1983, 21(4):197-202.
38. Armendariz E, Chelluri L, Ptachcinski R Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med 1990, 18(6):675-676.
39. Oe PL, Simonian S, Verhoef J Pharmacokinetics of the new penicillins. Amoxycillin and flucloxacillin in patients with terminal renal failure undergoing haemodialysis. Chemotherapy 1973, 19(5):279-288.
40. Muther RS, Bennett WM Peritoneal clearance of amphotericin B and 5-fluorocytosine. West J Med 1980, 133(2):157-160.
41. Block ER, Bennett JE, Livoti LG, Klein WJ, MacGregor RR, Henderson L Flucytosine and amphotericin B: Hemodialysis effects on the plasma concentration and clearance. Ann Intern Med 1974, 80(5):613-617.
42. Cotterill S Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 1995, 36(5):773-780.
43. Jusko WJ, Lewis GP, Schmitt GW Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther 1973, 14(1):90-99.
44. Golper TA, Pulliam J, Bennett WM Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med 1985, 145(9):1651-1652.
45. Kent JR, Almond MK, Dhillon S Azithromycin: An assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int 2001, 21(4):372-377.
46. Berman SJ, Boughton WH, Sugihara JG, Wong EG, Sato MM, Siemsen AW Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis. Antimicrob Agents Chemother 1978, 14(3):281-283.
47. Gartenberg G, Meyers BR, Hirschmann SZ, Srulevitch E Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis. J Antimicrob Chemother 1979, 5(4):465-470.
48. Marx MA, Frye RF, Matzke GR, Golper TA Cefazolin as empiric therapy in hemodialysis-related infections: Efficacy and blood concentrations. Am J Kidney Dis 1998, 32(3):410-414.
49. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999, 19(1):65-70.
50. Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother 1992, 36(12):2676-2680.
51. Wong KM, Chan WK, Chan YH, Li CS Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant 1999, 14(9):2265-2266.
52. Barbhaiya RH, Knupp CA, Pfeffer M, et al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1992, 36(7):1387-1391.
53. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J 1987, 6(10):963-970.
54. Guay DR, Meatherall RC, Harding GK, Brown GR Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 1986, 30(3):485-490.
55. Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 1985, 38(3):285-289.
56. Fillastre JP, Leroy A, Humbert G, Godin M Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother 1980, 6(A):103-111.
57. Hoffler D, Koeppe P, Corcilius M, Przyklinik A Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection 1990, 18(3):157-162.
58. Borin MT, Hughes GS, Kelloway JS, Shapiro BE, Halstenson CE Disposition of cefpodoxime proxetil in hemodialysis patients. J Clin Pharmacol 1992, 32(11):1038-1044.
59. Johnson CA, Ateshkadi A, Zimmerman SW, et al. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1993, 37(12):2650-2655.
60. Shyu WC, Pittman KA, Wilber RB, Matzke GR, Barbhaiya RH Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol 1991, 31(4):362-371.
61. Welage LS, Schultz RW, Schentag JJ Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 1984, 25(2):201-204.
62. Nikolaidis P, Tourkantonis A Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol 1985, 24(3):142-146.
63. Kinowski JM, de la Coussaye JE, Bressolle F, et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother 1993, 37(3):464-473.
64. Losno GR, Santivanez V, Battilana CA Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis. Chemotherapy 1988, 34(4):261-266.
65. Matzke GR, Frye RF, Joy MS, Palevsky PM Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000, 20(6):635-643.
66. Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 1988, 30(5):282-286.
67. Konishi K, Suzuki H, Hayashi M, Saruta T Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother 1993, 31(3):413-420.
68. Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP Pharmacokinetics of ciprofloxacin tablets in renal failure: Influence of haemodialysis. Eur J Clin Pharmacol 1987, 31(5):589-593.
69. Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol 1978, 14(6):435-439.
70. Nissenson AR, Wilson C, Holazo A Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. Am J Nephrol 1987, 7(4):270-274.
71. Paap CM, Nahata MC Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP 1989, 23(9):646-654.
72. Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int J Clin Pharmacol Ther Toxicol 1986, 24(9):460-464.
73. Gill KS, Wood MJ The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996, 31(1):1-8.
74. Dudley MN Clinical pharmacology of fluconazole. Pharmacotherapy 1990, 10(6/3):141S-145S.
75. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994, 14(4):502-505.
76. Aweeka FT, Jacobson MA, Martin-Munley S, et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20(4):350-357.
77. Combarnous F, Fouque D, Bernard N, et al. Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. Eur J Clin Pharmacol 1994, 46(4):379-381.
78. Boulieu R, Bastien O, Bleyzac N Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993, 15(2):105-107.
79. Golper TA, Pulliam J, Bennett WM Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med 1985, 145(9):1651-1652.
80. Somani P, Freimer EH, Gross ML, Higgins JT Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1988, 32(4):530-534.
81. Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. BrJ Clin Pharmacol 1984, 18(2):183-193.
82. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999, 159(5/1):1580-1584.
83. Ellard GA Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993, 64(2):169-181.
84. Daneshmend TK, Warnock DW Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988, 14(1):13-34.
85. Tegeder I, Neumann F, Bremer F, Brune K, Lotsch J, Geisslinger G Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999, 65(1):50-57.
86. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000, 28(3):632-637.
87. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993, 37(2):229-233.
88. Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ Metronidazole pharmacokinetics in patients with acute renal failure. J Antimicrob Chemother 1984, 13(2):183-189.
89. Ruedy J The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Can Med Assoc J 1966, 94(6):257-261.
90. Conte JE Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 1991, 163(1):169-175.
91. Conte JE, Upton RA, Lin ET Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis 1987, 156(6):885-890.
92. Thompson MI, Russo ME, Matsen JM, Atkin-Thor E Piperacillin pharmacokinetics in subjects with chronic renal failure. Antimicrob Agents Chemother 1981, 19(3):450-453.
93. Francke EL, Appel GB, Neu HC Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. Antimicrob Agents Chemother 1979, 16(6):788-791.
94. Debruyne D, Ryckelynck JP, Hurault DL, Moulin M Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis. J Pharm Sci 1990, 79(2):99-102.
95. Parry MF, Neu HC Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis 1976, 133(1):46-49.
96. Wise R, Reeves DS, Parker AS Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis. Antimicrob Agents Chemother 1974, 5(2):119-120.
97. Lockwood WR, Bower JD Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother 1973, 3(1):125-129.
98. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol 1986, 26(8):686-689.
99. Izzedine H, Mercadal L, Aymard G, et al. Neurotoxicity of valacy-clovir in peritoneal dialysis: A pharmacokinetic study. Am J Nephrol 2001, 21(2):162-164.
100. Smiley ML, Murray A, de Miranda P Valacyclovir HCl (Valtrex): An acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Adv Exp Med Biol 1996, 394:33-39.
101. Valcyte (product information): Nertley, N.J.: Roche Lab Inc.
102. Kandrotas RJ, Oles KS, Gal P, Love JM Carbamazepine clearance in hemodialysis and hemoperfusion. DICP 1989, 23(2):137-140.
103. Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 1980, 17(3):429-438.
104. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E Pharmacokinetics of lamotrigine in patients with renal impairment: Influence of haemodialysis. Drugs Exp Clin Res 1993, 19(1):25-32.
105. Garnett WR Lamotrigine: Pharmacokinetics. J Child Neurol 1997, 12(1):S10-S15.
106. Porto I, John EG, Heilliczer J Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997, 17(4):832-835.
107. Czajka PA, Anderson WH, Christoph RA, Banner W A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol 1980, 20(10):565-569.
108. Lapierre O, Dubreucq JL, Beauchemin MA, Vinet B Valproic acid intoxication in a patient with bipolar disorder and chronic uremia. Can J Psychiatry 1999, 44(2):88.
109. Bruni J, Wang LH, Marbury TC, Lee CS, Wilder BJ Protein binding of valproic acid in uremic patients. Neurology 1980, 30(5):557-559.
110. Orr JM, Farrell K, Abbott FS, Ferguson S, Godolphin WJ The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. Eur J Clin Pharmacol 1983, 24(3):387-390.
111. Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M Pharmacokinetics of amlodipine in renal impairment. Eur J Clin Pharmacol 1989, 36(2):205-208.
112. Laher MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 1988, 12(7):S60-S63.
113. Wan SH, Koda RT, Maronde RF Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol 1979, 7(6):569-574.
114. Flouvat B, Decourt S, Aubert P, et al. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. BrJ Clin Pharmacol 1980, 9(4):379-385.
115. Ferguson RK, Rotmensch HH, Vlasses PH Clinical use of capto-pril. Illustrative cases. JAMA 1982, 247(15):2117-2119.
116. Sica DA, Gehr TW, Fernandez A Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Safety 2000, 22(5):350-360.
117. Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron 1986, 44(4):324-328.
118. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ Elimination kinetics of captopril in patients with renal failure. Kidney Int 1984, 25(6):942-947.
119. Lowenthal DT, Saris SD, Paran E, Cristal N The use of transdermal clonidine in the hypertensive patient with chronic renal failure. Clin Nephrol 1993, 39(1):37-43.
120. Rosansky SJ, Johnson KL, McConnell J Use of transdermal clonidine in chronic hemodialysis patients. Clin Nephrol 1993, 39(1):32-36.
121. Doherty JE, Flanigan WJ, Perkins WH, Ackerman GL Studies with tritiated digoxin in anephric human subjects. Circulation 1967, 35(2):298-303.
122. Paulson MF, Welling PG Calculation of serum digoxin levels in patients with normal and impaired renal function. J Clin Pharmacol 1976, 16(11/12):660-665.
123. Iisalo E, Forsstrom J Elimination of digoxin during maintenance haemodialysis. Ann Clin Res 1974, 6(4):203-206.
124. Pancorbo S, Comty C Digoxin pharmacokinetics in continuous peritoneal dialysis. Ann Intern Med 1980, 93(4):639.
125. Golper TA, Bennett WM Drug removal by continuous arteriovenous haemofiltration: A review of the evidence in poisoned patients. Med Toxicol Adverse Drug Exp 1988, 3(5):341-349.
126. Sica DA, Cutler RE, Parmer RJ, Ford NF Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991, 20(5):420-427.
127. Mason NA Angiotensin-converting enzyme inhibitors and renal function. DICP 1990, 24(5):496-505.
128. Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 1985, 56(11):14F-18F.
129. Flaherty JF, Wong B, La Follette G, Warnock DG, Hulse JD, Gambertoglio JG Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther 1989, 45(3):321-327.
130. Wood AJ, Ferry DG, Bailey RR Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol 1982, 13(1):81S-86S.
131. Halstenson CE, Opsahl JA, Pence TV, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther 1986, 40(4):462-468.
132. Halstenson CE, Opsahl JA, Wright CE, et al. Disposition of minoxidil in patients with various degrees of renal function. J Clin Pharmacol 1989, 29(9):798-802.
133. Spital A, Scandling JD Nifedipine in continuous ambulatory peritoneal dialysis. Arch Intern Med 1983, 143(10):2025.
134. Kleinbloesem CH, van Brummelen P, Woittiez AJ, Faber H, Breimer DD Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet 1986, 11(4):316-322.
135. Herrera J, Vukovich RA, Griffith DL Elimination of nadolol by patients with renal impairment. Br J Clin Pharmacol 1979, 7(2):227S-231S.
136. Swan SK, Bennett WM Drug dosing guidelines in patients with renal failure. West J Med 1992, 156(6):633-638.
137. Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG Propranolol disposition in renal failure. Br J Clin Pharmacol 1980, 10(6):561-566.
138. Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther 1974, 16(5/1):761-769.
139. Bianchetti G, Graziani G, Brancaccio D, et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976, 1(5):373-384.
140. Follath F, Wenk M, Vozeh S, et al. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 1983, 34(5):638-643.
141. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Theil DH The clearance of cyclosporine by hemodialysis. J Clin Pharmacol 1984, 24(11/12):528-531.
142. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997, 12(8):1668-1671.
143. MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000, 57(3):1164-1168.
144. Bullingham RE, Nicholls AJ, Kamm BR Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34(6):429-455.
145. Frey BM, Frey FJ Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990, 19(2):126-146.
146. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991, 23(6):2736-2740.
147. Gammans RE, Mayol RF, LaBudde JA Metabolism and disposition of buspirone. Am J Med 1986, 80(3B):41-51.
148. Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR Effect of haemodialysis on the pharmacokinetics of cetirizine. EurJClin Pharmacol 1990, 38(1):67-69.
149. Matzke GR, Chan GL, Abraham PA Codeine dosage in renal failure. Clin Pharm 1986, 5(1):15-16.
150. Buckley MM, Sorkin EM Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992, 44(3):465-497.
151. Polkinghorne KR, McMahon LP, Becker GJ Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002, 40(5):990-995.
152. Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey GA Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988, 34(1):41-46.
153. Saima S, Echizen H, Yoshimoto K, Ishizaki T Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. J Clin Pharmacol 1990, 30(2):159-162.
154. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol 1988, 26(3):315-321.
155. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984, 36(1):138-144.
156. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR Fluoxetine: Clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985, 46(3/2):14-19.
157. Bailey RR, Sharman JR, O'Rourke J, Buttimore AL Haemodialysis and forced diuresis for tricyclic antidepressant poisoning. Br Med J 1974, 4(5938):230-231.
158. Andersson T Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996, 31(1):9-28.
159. Barradell LB, Faulds D, McTavish D Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992, 44(2):225-250.
160. Clericetti N, Beretta-Piccoli C Lithium clearance in patients with chronic renal diseases. Clin Nephrol 1991, 36(6):281-289.
161. Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol 1990, 30(4):364-371.
162. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991, 47(1):13-19.
163. Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of [14C] omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986, 40(3):344-351.
164. Howden CW, Payton CD, Meredith PA, et al. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. EurJClin Pharmacol 1985, 28(6):637-640.
165. Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 1989, 350:89-90.
166. McFadyen ML, Folb PI, Miller R, Keeton GR, Marks IN Pharmacokinetics of ranitidine in patients with chronic renal failure. Eur J Clin Pharmacol 1983, 25(3):347-351.
167. Zech PY, Chau NP, Pozet N, Labeeuw M, Hadj-Aissa A Ranitidine kinetics in chronic renal impairment. Clin Pharmacol Ther 1983, 34(5):667-672.
168. Gladziwa U, Krishna DR, Klotz U, et al. Pharmacokinetics of ranitidine in patients undergoing haemofiltration. Eur J Clin Pharmacol 1988, 35(4):427-430.
169. Blowey DL Principles of drug administration in children receiving renal replacement therapy. Pediatric Dialysis 2004, 545-565. Kluwer Academic Publishers, Great Britain. B.A. Warady, F.S. Schaefer, R.N. Fine, S.R. Alexander (Eds.).